Navigation Links
Roche Files IND for Second Genmab Antibody
Date:12/20/2007

Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a

Genmab Antibody

COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration. Genmab will receive a milestone payment from Roche which does not influence Genmab's financial guidance for 2007.

Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration to Genmab could be USD 100 million, plus royalties.

"This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab's seventh antibody to enter clinical development overall," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "Our partnership with Roche continues to bear fruit and add value to Genmab's expanding product pipeline."

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.

As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's prod
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 The Remedy ... growth strategy for the specialty pharmacy industry, will be ... 2015 Armada Specialty Pharmacy Summit. The Summit will be ... Las Vegas and is the largest annual gathering for ... in attendance, from pharmacy providers, pharma/biotech manufacturers, and payers, ...
(Date:5/5/2015)... 2015  23andMe, Inc., the leading personal genetics company, ... Study in collaboration with Pfizer Inc. The companies ... more commonly known as lupus, into the study to ... is also in collaboration with the Lupus Research Institute, ... Approximately 1.5 million people in the U.S. ...
(Date:5/5/2015)... 5, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... continue trading on OTCQB  Marketplace, the market for ... allows for a continuous public market for trading ... real-time quotes and market information on us through ... Marketplace includes U.S. and international companies in venture ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... March 13 Proteon Therapeutics, Inc.,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... appointed,Gregory D. Phelps, a seasoned biopharmaceutical executive, ... brings more than 30 years of executive,leadership ...
... Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended December,31, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved the ...
... FAIRFIELD, New Jersey, March 13, "The new Stonegate ... as the only biopharma company that,manufactures peptides by ... systems to administer the peptides. Since the launch ... has,captured a near dominant 49% market share of ...
Cached Biology Technology:Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... typically viewed as detrimental, plant pathologists with the American ... successful, eco-friendly tool for managing weeds. , ... is considered as one of the alternative weed control ... of chemical herbicides is not permitted or feasible," said ...
... was used to help monitor the health of Florida's coral ... August and September. , The project was the first comprehensive ... Marine Sanctuary that stretches about 300 miles from Martin County ... trying to determine why some reefs are resilient to environmental ...
... of malaria hits pregnant women and children the hardest. A ... in Uganda has now produced some important findings on how ... falciparium is the name of by far the most virulent ... particularly dangerous in that it also infects the placenta of ...
Cached Biology News:Fight weeds with plant pathogens 2NASA satellite data helps assess the health of Florida's coral reef 2NASA satellite data helps assess the health of Florida's coral reef 3New findings could lead to vaccine for severe malaria 2
... Doublestain System is a high-sensitivity peroxidase ... The kit is intended for use ... of two different antigens within the ... suitably diluted rabbit and mouse primary ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... VAMP-2 (Vesicle-Associated Membrane Protein 2, ... not share homology with any ... It is expected that the ... human, Macaca multata and bovine ...
... locus encodes two unrelated proteins both of ... the cell cycle in a p53-dependent manner. ... rapid degradation of mdm2 proteinrequired for mdm2 ... This interaction is mediated by the ...
Biology Products: